Perrigo Company, a leading global healthcare supplier, has initiated market launch and made its first shipments of the authorised generic version of LEO Pharma A/S' Taclonex ointment (calcipotriene 0.005per cent/betamethasone dipropionate 0.064 per cent).

Taclonex ointment (calcipotriene 0.005 per cent / betamethasone dipropionate 0.064 per cent) is indicated for the topical treatment of plaque psoriasis of the scalp and body in patients 18 years and older. Brand sales were approximately $110 million over the last 52-weeks according to Symphony Health Solutions.

Perrigo's chairman, president and chief executive officer Joseph C Papa stated, "This product was the result of the continued hard work and dedication of our Perrigo Rx team. This launch is another example of Perrigo's investment and commitment to making quality healthcare more affordable for consumers."

From its beginnings as a packager of generic home remedies in 1887, Perrigo Company headquartered in Ireland, has grown to become a leading global healthcare supplier. Perrigo develops, manufactures and distributes over-the-counter (OTC) and generic prescription (Rx) pharmaceuticals, nutritional products and active pharmaceutical ingredients (API), and receives royalties from Multiple Sclerosis drug Tysabri.

The company is the world's largest manufacturer of OTC healthcare products for the store brand market and an industry leader in pharmaceutical technologies. Perrigo's mission is to offer uncompromised "Quality Affordable Healthcare Products" and it does so across a wide variety of product categories primarily in the United States, United Kingdom, Mexico, Israel and Australia, as well as more than 40 other key markets worldwide, including Canada, China and Latin America.”